Platelet activation in obese women: Role of inflammation and oxidant stress

JAMA

Volumn 288, Issue 16, 2002, Pages 2008-2014

  Davì, Giovanni ^a   Guagnano, Maria Teresa ^a   Ciabattoni, Giovanni ^a   Basili, Stefania ^b   Falco, Angela ^a   Marinopiccoli, Marina ^a   Nutini, Michele ^a   Sensi, Sergio ^a   Patrono, Carlo ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CREATININE; INSULIN; LEPTIN; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN;

ABDOMEN; ADULT; ARTICLE; BODY MASS; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIET THERAPY; FEMALE; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID PEROXIDATION; MULTIPLE REGRESSION; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; URINARY EXCRETION; WEIGHT REDUCTION;

EID: 0037164094     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.16.2008     Document Type: Article

References (47)

1. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation. 1987;76:6-14.
2. Davi G, Averna M, Catalano I, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 1992;85:1792-1798.
3. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769-1774.
4. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.
5. Ridker PM. High-sensitivity C-reactive protein. Circulation. 2001;103:1813-1818.
6. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep. 1999;1:156-164.
7. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383-9387.
8. 2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3230-3235.
9. 2α and platelet activation in diabetes mellitus. Circulation. 1999;99:224-229.
10. Davi G, Di Minno G, Coppola A, et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation. 2001;104:1124-1128.
11. Solomon CG, Manson JE. Obesity and mortality. Am J Clin Nutr. 1997;66(4 suppl):1044S-1050S.
12. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med. 2000;160:898-904.
13. Pouliot MC, Desprès JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter. Am J Cardiol. 1994;73:460-468.
14. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Human subcutaneous adipose tissue secretes interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196-4200.
15. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-1197.
16. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity. Geneva, Switzerland: World Health Organization; June 3-5, 1997. WHO/NUT/NCD/98.1.
17. Crepaldi G, Belfiore F, Bosello O, et al. Italian consensus conference-overweight, obesity and health. Int J Obes. 1991;15:781-790.
18. 2 in man. Biochim Biophys Acta. 1989;992: 66-70.
19. 2 in human plasma and urine. Biochim Biophys Acta. 1987; 918:293-297.
20. 2α excretion in man. J Pharmacol Exp Ther. 1995;275:94-100.
21. Lidue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Iin Clin Biochem. 1998;35:745-753.
22. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body mass index and mortality. N Engl J Med. 1998;338:1-8.
23. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999;341:1097-1105.
24. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease. Atherosclerosis. 2000;148:209-214.
25. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress. Diabetes. 2001;50:159-165.
26. Brook RD, Bard RL, Rubenfire M, Ridker PM, Rajagopalan S. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol. 2001;88: 1264-1269.
27. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal man. J Clin Invest. 1986;77:590-594.
28. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983;67:1174-1177.
29. Patrono C, FitzGerald GA. Isoprostanes. Arterioscler Thromb Vasc Biol. 1997;17:2309-2315.
30. Nakao C, Ookawara T, Sato Y, et al. Extracellular superoxide dismutase in tissues from obese mice. Free Radic Res. 2000;33:229-241.
31. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension. 2001;37:554-560.
32. Laight DW, Desai KM, Gopaul NK, Anggard EE, Carrier MJ. F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat. Eur J Pharmacol. 1999;377:89-92.
33. Ceriello A. Oxidative stress and glycemic regulation. Metabolism. 2000;49:27-29.
34. Bouloumié A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999;13:1231-1238.
35. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol. 1999;19:972-978.
36. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical arteriosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986-1991.
37. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein. Arterioscler Thromb Vasc Biol. 2001;21:961-967.
38. Heinrich PC, Castett JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621-626.
39. Pasceri V, Willerson JT, Yeh ET. Direct proinfiammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
40. Meade EA, McIntyre TM, Zimmerman GA, et al. Peroxisone proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem. 1999;274: 8328-8334.
41. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol. 2001;154: 485-490.
42. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets red uce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol. 2001;21:968-970.
43. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs. Chest. 2001;119:39S-63S.
44. Patrignani P, Panara MR, Tacconelli S, et al. A randomized, placebo-controlled dose-finding study of the effect of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation. 2000;102:539-545.
45. Willett WC, Stampfer MJ. What vitamins should I be taking, doctor? N Engl J Med. 2001;345:1819-1824.
46. Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med. 2002;346:1468-1474.
47. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk. Lancet. 2001;357:89-95.